ArticleiMeta2026
Environmental chemicals and the tumor immune microenvironment.
Article in iMeta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impact of representative environmental chemicals on tumor immune microenvironment (TIME). Representative environmental chemicals are ubiquitously distributed across air, soil, aquatic systems, and biota. These toxicants enter the human body via multiple exposure routes, including inhalation, dietary intake, and dermal absorption, subsequently accumulating in vital organs (such as the liver, lungs, kidneys, and intestines) as well as within tumor tissues. By disrupting physiological homeostasis, they impair the functionality of critical biological systems, including the metabolic, nervous, circulatory, and immune systems. Notably, within tumor tissues, these chemicals remodel the TIME by suppressing antitumor immunity and compromising the efficacy of immunotherapy, thereby promoting tumor initiation and progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.